Davern Capital Partners, LP 13F: Quarter-over-Quarter Portfolio Changes
Davern Capital Partners, LP reported a disclosed portfolio value of approximately $586.5 million in its latest SEC Form 13F-HR filing for Q2 2026, up 60.9% quarter on quarter. Over the quarter, the fund initiated 3 new positions, bought more shares in 10 holdings, trimmed 2 holdings, and exited 5 positions.
Davern Capital Partners, LP's top buy was a new stake in Alnylam Pharmaceuticals INC (ALNY) , equal to 5.8% of the disclosed portfolio. Its top sell was Pfizer INC (PFE) . The fund exited the position completely after it had accounted for 12.3% of the previous portfolio.
New PositionsQ2 2026
Securities disclosed for the first time in Q2 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | ALNY | 5.8% | History → |
| VERA THERAPEUTICS INC | VERA | 3.6% | Holders → |
| AVALO THERAPEUTICS INC | AVTX | 1.5% | Holders → |
Top BuysQ2 2026
The fund's top buys among existing positions in Q2 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| STRUCTURE THERAPEUTICS INC | GPCR | +2.4% | +252.7% | History → |
| INSMED INC | INSM | +2.0% | +206.6% | History → |
| BIONTECH SE | BNTX | +4.5% | +147.3% | History → |
| ROYALTY PHARMA PLC | RPRX | +4.2% | +122.3% | History → |
| ROIVANT SCIENCES LTD | ROIV | +5.0% | +121.3% | History → |
| REGENERON PHARMACEUTICALS | REGN | +0.4% | +106.8% | History → |
| IONIS PHARMACEUTICALS INC | IONS | +2.8% | +106.4% | History → |
| MINERALYS THERAPEUTICS INC | MLYS | +0.6% | +92.0% | Holders → |
| PROCEPT BIOROBOTICS CORP | PRCT | +-0.0% | +78.0% | Holders → |
| GENERATE BIOMEDICINES INC | GENB | +0.3% | +39.4% | Holders → |
Top SellsQ2 2026
The fund's top sells among positions it retained in Q2 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| NATERA INC | NTRA | -2.4% | 17.4% | History → |
| LEGEND BIOTECH CORP | LEGN | -0.7% | 9.4% | History → |
Full ExitsQ2 2026
Positions present in the prior 13F-HR filing that no longer appear in Q2 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| PFIZER INC | PFE | 12.3% |
| ARGENX SE | ARGX | 7.0% |
| ELI LILLY & CO | LLY | 6.9% |
| ABIVAX SA | ABVX | 2.4% |
| VIRIDIAN THERAPEUTICS INC | VRDN | 1.6% |
Net Portfolio Value ChangeQ2 2026
- $0.4BPrior quarter
- $0.6BCurrent quarter
- +$0.2BNet delta
- +60.9%% change
Methodology & FAQ
How Davern Capital Partners, LP Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Davern Capital Partners, LP: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description, including how confidential treatment filings are handled, is documented in the Methodology.
What stocks did Davern Capital Partners, LP buy in Q2 2026?
In Q2 2026, Davern Capital Partners, LP initiated 3 new positions (ALNYLAM PHARMACEUTICALS INC (ALNY), VERA THERAPEUTICS INC (VERA), AVALO THERAPEUTICS INC (AVTX)); bought more shares of STRUCTURE THERAPEUTICS INC (GPCR), INSMED INC (INSM), BIONTECH SE (BNTX), ROYALTY PHARMA PLC (RPRX), ROIVANT SCIENCES LTD (ROIV) (the largest 5 of 10 adds).
What stocks did Davern Capital Partners, LP sell in Q2 2026?
In Q2 2026, Davern Capital Partners, LP fully sold 5 positions (PFIZER INC (PFE), ARGENX SE (ARGX), ELI LILLY & CO (LLY), ABIVAX SA (ABVX), VIRIDIAN THERAPEUTICS INC (VRDN)); reduced holdings in NATERA INC (NTRA), LEGEND BIOTECH CORP (LEGN).
Which positions did Davern Capital Partners, LP initiate in Q2 2026?
Davern Capital Partners, LP established 3 new positions in Q2 2026: ALNYLAM PHARMACEUTICALS INC (ALNY, 5.8%), VERA THERAPEUTICS INC (VERA, 3.6%), AVALO THERAPEUTICS INC (AVTX, 1.5%).
Which existing positions saw the largest allocation increases for Davern Capital Partners, LP in Q2 2026?
Of 10 existing positions with share-count increases in Q2 2026, the largest were: STRUCTURE THERAPEUTICS INC (GPCR, +2.4% weight, +252.7% shares), INSMED INC (INSM, +2.0% weight, +206.6% shares), BIONTECH SE (BNTX, +4.5% weight, +147.3% shares), ROYALTY PHARMA PLC (RPRX, +4.2% weight, +122.3% shares), ROIVANT SCIENCES LTD (ROIV, +5.0% weight, +121.3% shares), REGENERON PHARMACEUTICALS (REGN, +0.4% weight, +106.8% shares), IONIS PHARMACEUTICALS INC (IONS, +2.8% weight, +106.4% shares), MINERALYS THERAPEUTICS INC (MLYS, +0.6% weight, +92.0% shares), PROCEPT BIOROBOTICS CORP (PRCT, +-0.0% weight, +78.0% shares), GENERATE BIOMEDICINES INC (GENB, +0.3% weight, +39.4% shares).
Which positions did Davern Capital Partners, LP fully exit in Q2 2026?
Davern Capital Partners, LP fully exited 5 positions in Q2 2026: PFIZER INC (PFE, last-reported weight 12.3%), ARGENX SE (ARGX, last-reported weight 7.0%), ELI LILLY & CO (LLY, last-reported weight 6.9%), ABIVAX SA (ABVX, last-reported weight 2.4%), VIRIDIAN THERAPEUTICS INC (VRDN, last-reported weight 1.6%).
Which existing positions saw the largest allocation reductions for Davern Capital Partners, LP in Q2 2026?
Of 2 existing positions with share-count reductions in Q2 2026, the largest were: NATERA INC (NTRA, -2.4% weight, -17.4% shares), LEGEND BIOTECH CORP (LEGN, -0.7% weight, -9.4% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.